



CIN : L99999MH1951PLC008485

Regd. Office : A-1601, Thane One, DIL Complex, Ghodbunder Road, Majiwada, Thane (West) 400 610, Maharashtra, India
Tel : +91-22-67980888 , ● Fax : +91-22-67980899 , ● Email : contact@dil.net , ● Website: www.dil.net

Ref: DIL:DIL/BSE/2018-19/F.No.:S-23/ DE05

December 31, 2018

**Corporate Relations
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai – 400 001**

Dear Sir,


Sub.: Intimation regarding receipt of awards by Fermenta Biotech Limited, Company's subsidiary

Ref: Scrip Code: 506414

We would like to inform that Fermenta Biotech Limited, Company's subsidiary, has received "Excellence in Corporate Social Responsibility", "Excellence in Export Promotion" and "Pharma International Excellence" awards at India Pharma Awards 2018.

Award details and related information is enclosed herewith for the information of stakeholders.

Thanking you,

For DIL LIMITED

SRIKANT N. SHARMA
COMPANY SECRETARY

CS Membership No: F3617
A-1601, Thane One, DIL Complex, Ghodbunder Road, Majiwade, Thane (W) 400610

Encl: As above

DIL LIMITED Subsidiary FERMENTA BIOTECH LIMITED

Receives “Excellence in Corporate Social Responsibility”, “Excellence in Export Promotion” and “Pharma International Excellence” Awards at India Pharma Awards 2018

Fermenta Biotech Limited, a 91.2% subsidiary of DIL Limited, has received “Excellence in Corporate Social Responsibility”, “Excellence in Export Promotion” and “Pharma International Excellence” awards at India Pharma Awards 2018. The awards were given during the recently concluded Pharma Week at CPhI India – South East Asia’s largest pharmaceutical event.

Commenting on the Award Mr. Prashant Nagre, CEO, Fermenta Biotech Limited said,

“The awards are recognition of the efforts put in by the company to remain ahead of the curve in the competitive global environment.

As a responsible citizen, it has always been our belief to give back to the community we are present in. The award was for empowering local communities to create sustainable growth.

The excellence in export promotion award recognises our steady growth over the years and demonstration of increasing our global footprint to across 50+ countries over six continents.

The Pharma International Excellence Award honored FBL for achieving success in international markets through world class strategy and operations. From re-engineering business processes through implementation of SAP and CRM initiative like salesforce.com to embracing best in class practices for value enhancement across verticals, FBL is focused on a robust and sustainable future.

We are trusted partners for our customers and have consistently delivered on quality products with help of our R&D and Internationally benchmarked manufacturing practices. This has helped us improve our profitability over the years. The Export Promotion award along with the International Excellence award are a testimony of our capabilities, product quality and a highly experienced team committed to consistent delivery.”



For Immediate Release

About DIL Limited:

DIL holds 91.2% equity stake in Fermenta Biotech Limited (FBL), which was incorporated in 1986.

FBL is engaged in manufacturing of Vitamin D3, other specialty APIs, biological enzymes and also offers integrated biotech based environmental solutions. FBL has 2 manufacturing facilities:

- Kullu in Himachal Pradesh – cGMP certified and currently manufactures Vitamin D3, specialty API’s and Enzymes
- Dahej SEZ – set up in 2011 and manufactures Vitamin D3

DIL has developed premium office spaces named ‘THANE ONE’, with a total leasable area of 200,000 sq. ft., which is currently about 95% occupied.

For more information about the Company and its businesses, please visit our website www.dil.net

Safe Harbor:

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

For further details please contact:

Company	Investor Relations Advisors
<p>DIL Limited CIN No: L99999MH1951PLC008485 Name: Sumesh Gandhi Email id: sumesh.gandhi@dil.net</p>	<p>Strategic Growth Advisors Pvt Ltd. CIN No: U74140MH2010PTC204285 Rahul Agarwal / Mandar Chavan Email id: rahul.agarwal@sgapl.net mandar.chavan@sgapl.net Tel No: +91 79770 90416 / +91 96993 82195</p>